Transmedics Group Inc (NASDAQ: TMDX) has a price-to-earnings ratio that is above its average at 102.97x. The stock has a 36-month beta value of 2.07. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TMDX is 32.42M, and at present, short sellers hold a 25.99% of that float. On November 13, 2024, the average trading volume of TMDX was 1.40M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TMDX) stock’s latest price update
Transmedics Group Inc (NASDAQ: TMDX)’s stock price has soared by 5.14 in relation to previous closing price of 91.41. Nevertheless, the company has seen a gain of 11.31% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-12 that TransMedics’ Q3 results were weak, with revenue declining sequentially due to US transplant volume headwinds and scheduled aircraft maintenance. While the growth of TransMedics’ current business is likely to continue moderating, there remain large opportunities internationally and in other organs. This is highlighted by the fact that TransMedics reiterated its longer-term transplant volume target, despite current weakness.
TMDX’s Market Performance
Transmedics Group Inc (TMDX) has seen a 11.31% rise in stock performance for the week, with a -27.10% decline in the past month and a -43.45% plunge in the past quarter. The volatility ratio for the week is 5.89%, and the volatility levels for the past 30 days are at 5.49% for TMDX. The simple moving average for the past 20 days is -5.33% for TMDX’s stock, with a -21.49% simple moving average for the past 200 days.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with Oppenheimer repeating the rating for TMDX by listing it as a “Outperform.” The predicted price for TMDX in the upcoming period, according to Oppenheimer is $125 based on the research report published on October 29, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see TMDX reach a price target of $109, previously predicting the price at $208. The rating they have provided for TMDX stocks is “Buy” according to the report published on October 29th, 2024.
Robert W. Baird gave a rating of “Outperform” to TMDX, setting the target price at $200 in the report published on September 24th of the current year.
TMDX Trading at -24.91% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.81% of loss for the given period.
Volatility was left at 5.49%, however, over the last 30 days, the volatility rate increased by 5.89%, as shares sank -25.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.18% lower at present.
During the last 5 trading sessions, TMDX rose by +11.58%, which changed the moving average for the period of 200-days by +10.63% in comparison to the 20-day moving average, which settled at $101.54. In addition, Transmedics Group Inc saw 21.77% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Basile Edward M, who sale 6,750 shares at the price of $83.55 back on Nov 05 ’24. After this action, Basile Edward M now owns 732 shares of Transmedics Group Inc, valued at $563,994 using the latest closing price.
Khayal Tamer I, the Chief Commercial Officer of Transmedics Group Inc, sale 1,083 shares at $82.64 during a trade that took place back on Nov 01 ’24, which means that Khayal Tamer I is holding 20,843 shares at $89,499 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.59 for the gross margin
The net margin for Transmedics Group Inc stands at 0.08. The total capital return value is set at 0.04. Equity return is now at value 19.41, with 4.43 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 2.43. The interest coverage ratio of the stock is 2.91.
Currently, EBITDA for the company is -7.6 million with net debt to EBITDA at 3.64. When we switch over and look at the enterprise to sales, we see a ratio of 8.6. The receivables turnover for the company is 4.45for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.20.
Conclusion
To sum up, Transmedics Group Inc (TMDX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
